Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Sarcoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Neoplasms 2Inflammatory Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Liver Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 11Cisplatin 9Oxaliplatin 7Leucovorin 6Irinotecan 6Fluorouracil 5Taxes 3Radiotherapy 3Platinum 3Interleukin-12 Subunit p35 3Erlotinib Hydrochloride 3Capecitabine 3Albumin-Bound Paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3Trastuzumab 2Docetaxel 2Cyclophosphamide 2Carboplatin 2130-nm albumin-bound paclitaxel 2tipifarnib 1sargramostim 1pembrolizumab 1motexafin gadolinium 1merestinib 1guadecitabine 1fludarabine 1entinostat 1durvalumab 1dehydroftorafur 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gallbladder Neoplasms × Epirubicin × Clear all
NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

University of Nebraska

Phase 1 Completed
46 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡